| Neima Hadi, MD | |
|
455 Toll Gate Rd, Warwick, RI 02886-2759 | |
| (401) 737-7010 | |
| (401) 736-4546 |
| Full Name | Neima Hadi |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine |
| Experience | 8 Years |
| Location | 455 Toll Gate Rd, Warwick, Rhode Island |
| Accepts Medicare Assignments | May be. He may accept the Medicare-approved amount; you may be billed for more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1740638881 | NPI | - | NPPES |
| Facility Name | Location | Facility Type |
|---|---|---|
| South County Hospital Inc | Wakefield, RI | Hospital |
| Westerly Hospital | Westerly, RI | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Silver Spring Health Care Management Inc | 4688661127 | 118 |
| Hospital Medicine Associates Llc | 9234156985 | 168 |
News Archive
Ember Therapeutics, Inc., a company harnessing breakthroughs in brown fat biology and insulin sensitization to revolutionize the treatment of metabolic disease, today announced the publication of key preclinical data demonstrating that inhibition of the Transient Receptor Potential Vanilloid (TRPV) family of ion channels - specifically TRPV4 - resulted in activation of brown/beige fat and protection from diet-induced obesity, inflammation and insulin resistance. Ember holds an exclusive option to license these TRPV4 findings and technology.
The brain is a powerful organ that controls all the body processes, including movement. In some athletes, however, they usually experience a phenomenon called "choking," wherein their performance rapidly declines when they're under a lot of pressure.
Although drinking by U.S. adolescents has decreased during the last decade, more than 20 percent of U.S. high-school students continue to drink alcohol before the age of 14 years.
Tonix Pharmaceuticals Holding Corp., a specialty pharmaceutical company developing therapies for challenging disorders of the central nervous system, including fibromyalgia syndrome and post-traumatic stress disorder, will initiate a comparative pharmacokinetic and bioavailability study of TNX-102, a novel dosage oral formulation of cyclobenzaprine for the treatment of FM, following the U.S. Food and Drug Administration clearance of the Company's initial Investigational New Drug Application.
› Verified 4 days ago
| Entity Name | Silver Spring Health Care Management Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1861561193 PECOS PAC ID: 4688661127 Enrollment ID: O20080124000678 |
News Archive
Ember Therapeutics, Inc., a company harnessing breakthroughs in brown fat biology and insulin sensitization to revolutionize the treatment of metabolic disease, today announced the publication of key preclinical data demonstrating that inhibition of the Transient Receptor Potential Vanilloid (TRPV) family of ion channels - specifically TRPV4 - resulted in activation of brown/beige fat and protection from diet-induced obesity, inflammation and insulin resistance. Ember holds an exclusive option to license these TRPV4 findings and technology.
The brain is a powerful organ that controls all the body processes, including movement. In some athletes, however, they usually experience a phenomenon called "choking," wherein their performance rapidly declines when they're under a lot of pressure.
Although drinking by U.S. adolescents has decreased during the last decade, more than 20 percent of U.S. high-school students continue to drink alcohol before the age of 14 years.
Tonix Pharmaceuticals Holding Corp., a specialty pharmaceutical company developing therapies for challenging disorders of the central nervous system, including fibromyalgia syndrome and post-traumatic stress disorder, will initiate a comparative pharmacokinetic and bioavailability study of TNX-102, a novel dosage oral formulation of cyclobenzaprine for the treatment of FM, following the U.S. Food and Drug Administration clearance of the Company's initial Investigational New Drug Application.
› Verified 4 days ago
| Entity Name | Lifespan Physician Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1407116643 PECOS PAC ID: 2567455082 Enrollment ID: O20121029000368 |
News Archive
Ember Therapeutics, Inc., a company harnessing breakthroughs in brown fat biology and insulin sensitization to revolutionize the treatment of metabolic disease, today announced the publication of key preclinical data demonstrating that inhibition of the Transient Receptor Potential Vanilloid (TRPV) family of ion channels - specifically TRPV4 - resulted in activation of brown/beige fat and protection from diet-induced obesity, inflammation and insulin resistance. Ember holds an exclusive option to license these TRPV4 findings and technology.
The brain is a powerful organ that controls all the body processes, including movement. In some athletes, however, they usually experience a phenomenon called "choking," wherein their performance rapidly declines when they're under a lot of pressure.
Although drinking by U.S. adolescents has decreased during the last decade, more than 20 percent of U.S. high-school students continue to drink alcohol before the age of 14 years.
Tonix Pharmaceuticals Holding Corp., a specialty pharmaceutical company developing therapies for challenging disorders of the central nervous system, including fibromyalgia syndrome and post-traumatic stress disorder, will initiate a comparative pharmacokinetic and bioavailability study of TNX-102, a novel dosage oral formulation of cyclobenzaprine for the treatment of FM, following the U.S. Food and Drug Administration clearance of the Company's initial Investigational New Drug Application.
› Verified 4 days ago
| Entity Name | Hospital Medicine Associates Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1093758781 PECOS PAC ID: 9234156985 Enrollment ID: O20170816001446 |
News Archive
Ember Therapeutics, Inc., a company harnessing breakthroughs in brown fat biology and insulin sensitization to revolutionize the treatment of metabolic disease, today announced the publication of key preclinical data demonstrating that inhibition of the Transient Receptor Potential Vanilloid (TRPV) family of ion channels - specifically TRPV4 - resulted in activation of brown/beige fat and protection from diet-induced obesity, inflammation and insulin resistance. Ember holds an exclusive option to license these TRPV4 findings and technology.
The brain is a powerful organ that controls all the body processes, including movement. In some athletes, however, they usually experience a phenomenon called "choking," wherein their performance rapidly declines when they're under a lot of pressure.
Although drinking by U.S. adolescents has decreased during the last decade, more than 20 percent of U.S. high-school students continue to drink alcohol before the age of 14 years.
Tonix Pharmaceuticals Holding Corp., a specialty pharmaceutical company developing therapies for challenging disorders of the central nervous system, including fibromyalgia syndrome and post-traumatic stress disorder, will initiate a comparative pharmacokinetic and bioavailability study of TNX-102, a novel dosage oral formulation of cyclobenzaprine for the treatment of FM, following the U.S. Food and Drug Administration clearance of the Company's initial Investigational New Drug Application.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Neima Hadi, MD 455 Toll Gate Rd, Warwick, RI 02886-2759 Ph: (401) 737-7010 | Neima Hadi, MD 455 Toll Gate Rd, Warwick, RI 02886-2759 Ph: (401) 737-7010 |
News Archive
Ember Therapeutics, Inc., a company harnessing breakthroughs in brown fat biology and insulin sensitization to revolutionize the treatment of metabolic disease, today announced the publication of key preclinical data demonstrating that inhibition of the Transient Receptor Potential Vanilloid (TRPV) family of ion channels - specifically TRPV4 - resulted in activation of brown/beige fat and protection from diet-induced obesity, inflammation and insulin resistance. Ember holds an exclusive option to license these TRPV4 findings and technology.
The brain is a powerful organ that controls all the body processes, including movement. In some athletes, however, they usually experience a phenomenon called "choking," wherein their performance rapidly declines when they're under a lot of pressure.
Although drinking by U.S. adolescents has decreased during the last decade, more than 20 percent of U.S. high-school students continue to drink alcohol before the age of 14 years.
Tonix Pharmaceuticals Holding Corp., a specialty pharmaceutical company developing therapies for challenging disorders of the central nervous system, including fibromyalgia syndrome and post-traumatic stress disorder, will initiate a comparative pharmacokinetic and bioavailability study of TNX-102, a novel dosage oral formulation of cyclobenzaprine for the treatment of FM, following the U.S. Food and Drug Administration clearance of the Company's initial Investigational New Drug Application.
› Verified 4 days ago
Dr. Eric Mastrogiacomo, DO Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 455 Toll Gate Rd, Warwick, RI 02886 Phone: 401-737-7010 Fax: 401-736-4546 | |
Sajedabanu Momin, M.D. Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 455 Toll Gate Rd, Warwick, RI 02886 Phone: 260-443-4295 | |
Dr. Paul Francis Mckenney, M.D. Hospitalist Medicare: Not Enrolled in Medicare Practice Location: 33 Beach Park Ave, Warwick, RI 02886 Phone: 401-739-6929 | |
Dr. Manoj Gurung, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 455 Toll Gate Rd, Kent Hospital, Warwick, RI 02886 Phone: 401-737-7000 | |
Denise M Arcand, M.D. Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 455 Toll Gate Rd, Warwick, RI 02886 Phone: 401-737-7010 Fax: 401-736-4546 | |
Shereen A. Santee, DO Hospitalist Medicare: Medicare Enrolled Practice Location: 455 Toll Gate Rd, Warwick, RI 02886 Phone: 401-737-7010 Fax: 401-736-4546 | |
Dr. Yayra Musabek, M.D Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 455 Toll Gate Rd, Warwick, RI 02886 Phone: 401-737-7000 |